Evidence map›Paper›PMID 35152884›Full record

ReviewBMC cardiovascular disorders2022

Nilotinib related acute myocardial infarction with nonobstructive coronary arteries: a case report and literature review.

Weiwei Chen, Beibei Du, Kun Liu, Zhixi Yu, Xingtong Wang, Ping Yang

Open access · goldAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMC cardiovascular disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Nilotinib-Associated Multiple Silent Arterial Stenoses in a Patient with Chronic Myeloid LeukemiaTurkish journal of haematology : official journal of Turkish Society of Haematology · 2024
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Weiwei ChenDepartment of Cardiology, China-Japan Union Hospital of Jilin University, Xiantai, Street No. 126, Changchun, 130033, Jilin Province, China.
Beibei DuDepartment of Cardiology, China-Japan Union Hospital of Jilin University, Xiantai, Street No. 126, Changchun, 130033, Jilin Province, China. beibeidu2012@jlu.edu.cn.ORCID 0000-0002-0991-5798
Kun LiuDepartment of Cardiology, China-Japan Union Hospital of Jilin University, Xiantai, Street No. 126, Changchun, 130033, Jilin Province, China.
Zhixi YuDepartment of Cardiology, China-Japan Union Hospital of Jilin University, Xiantai, Street No. 126, Changchun, 130033, Jilin Province, China.
Xingtong WangDepartment of Hematology, The First Hospital of Jilin University, Jilin Provincial Hematology Research Institute, National Key Discipline in Hematology and Oncology, Changchun, 130021, Jilin Province, China.
Ping YangDepartment of Cardiology, China-Japan Union Hospital of Jilin University, Xiantai, Street No. 126, Changchun, 130033, Jilin Province, China.
Union Hospital · CNJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMyocardial Ischemia with No Obstructive Coronary Artery Disease (MINOCA) is a common cause of type 2 acute myocardial infarction (AMI) which requires careful differential diagnosis. Coronary artery spasm (CAS) syndrome is one etiology that can lead to MINOCA. Nilotinib, a targeted treatment for chronic myeloid leukemia (CML), has been reported to be related with increased risk of adverse vascular events. CASE PRESENTATION: A 67-year-old male patient was admitted to hospital with acute chest pain. He had a past medical history of CML and a history of treatment with nilotinib for 12 months. Coronary angiography (CAG) showed no significant stenosis. Since the onset of angina was generally in the early morning, and ECG and echocardiography suggested right coronary artery (RCA) disease, an ergonovine provocation test was performed to confirm the diagnosis of CAS. After intracoronary administration of ergonovine, middle and distal RCA showed over 90% vasoconstriction. Nilotinib related MINOCA, CAS and CML were diagnosed. Lifestyle changes (cessation of smoking), anti-spasmodics, statin treatment and adjustment of the nilotinib dose (from 200 mg bid, to 150 mg bid) were recommended for this patient. Six-month's follow-up showed good recovery with no onsets of angina.

conclusionsPhysicians should be vigilant to adverse vascular events when treating patients who have been prescribed nilotinib. It is suggested that in patients with MINOCA who have a history of treatment with nilotinib, CAS-induced MINOCA should be included in the differential diagnosis. Further studies are needed to clarify the mechanism and to find better management.

Indexed as

AgedAntineoplastic AgentsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMaleMINOCAProtein Kinase InhibitorsPyrimidinesSmoking CessationTreatment OutcomeVasodilator AgentsAntineoplastic AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsnilotinibProtein Kinase InhibitorsPyrimidinesVasodilator AgentsCase reportCoronary artery spasmErgonovine provocation testMyocardial Ischemia with No Obstructive Coronary Artery DiseaseNilotinibVascular adverse events

Identifiers

PMID35152884
PMCPMC8842974
OpenAlexW4212836138

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.